The anaemia of cancer: Death by a thousand cuts

Nature Reviews Cancer

Volumn 5, Issue 7, 2005, Pages 543-555

  Spivak, Jerry L ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIMETABOLITE; ANTINEOPLASTIC AGENT; CD34 ANTIGEN; ERYTHROPOIETIN; ERYTHROPOIETIN RECEPTOR; FAS LIGAND; FREE RADICAL; GAMMA INTERFERON; GAMMA INTERFERON RECEPTOR; HEMOGLOBIN; HEMOPOIETIC GROWTH FACTOR; HYPOXIA INDUCIBLE FACTOR 1; HYPOXIA INDUCIBLE FACTOR 1ALPHA; HYPOXIA INDUCIBLE FACTOR 1BETA; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; INTERLEUKIN 6; IRON; PROTEIN P53; RECOMBINANT ERYTHROPOIETIN; RNA; STEM CELL FACTOR; THROMBOPOIETIN; TRANSFERRIN; TUMOR MARKER; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; TUMOR PROMOTER; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANEMIA; BLOOD TRANSFUSION; CANCER RADIOTHERAPY; CANCER SURVIVAL; CELL METABOLISM; CELL PROLIFERATION; CLINICAL TRIAL; COLONY FORMING UNIT E; CYTOKINE PRODUCTION; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; ERYTHROID PRECURSOR CELL; ERYTHROPOIESIS; FATIGUE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; HUMAN; HYPOXEMIA; IRON METABOLISM; META ANALYSIS; METASTASIS; NONHUMAN; OUTCOMES RESEARCH; PARACRINE SIGNALING; PARANEOPLASTIC SYNDROME; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN SYNTHESIS; REVIEW; RISK FACTOR; SIGNAL TRANSDUCTION; SURVIVAL RATE; SYSTEMATIC REVIEW; TUMOR CELL; TUMOR GROWTH;

ANEMIA; ANOXIA; CARCINOGENS; CELL DEATH; ERYTHROPOIESIS; ERYTHROPOIETIN; ERYTHROPOIETIN, RECOMBINANT; HUMANS; NEOPLASMS; SIGNAL TRANSDUCTION;

EID: 21744439534     PISSN: 1474175X     EISSN: None     Source Type: Journal    
DOI: 10.1038/nrc1648     Document Type: Review

References (191)

1. Jemal, A. et al. Cancer statistics, 2004. CA Cancer J. Clin. 54, 8-29 (2004).
2. Berlin, N. I. Anemia of cancer. Ann. N. Y. Acad. Sci. 230, 209-211 (1974).
3. Tas, F. et al. Anemia in oncology practice: relation to diseases and their therapies. Am. J. Clin. Oncol. 25, 371-379 (2002).
4. Knight, K., Wade, S. & Balducci, L. Prevalence and outcomes of anemia in cancer: a systematic review of the literature. Am. J Med. 116 (Suppl. 7A), 11-26 (2004).
5. Groopman, J. E. & Itri, L. M. Chemotherapy-induced anemia in adults: incidence and treatment. J. Natl. Cancer Inst. 91, 1616-1634 (1999).
6. Caro, J. J., Salas, M., Ward, A. & Goss, G. Anemia as an independent prognostic factor for survival in patients with cancer: a systemic, quantitative review. Cancer 91, 2214-2221 (2001).
7. Nissenson, A. R., Goodnough, L. T. & Dubois, R. W. Anemia: not just an innocent bystander? Arch. Intern. Med. 163, 1400-1404 (2003).
8. Volberding, P. A. et al. Anemia in HIV infection: clinical impact and evidence-based management strategies. Clin. Infect. Dis. 38, 1454-1463 (2004).
9. Glaser, C. M. et al. Impact of hemoglobin level and use of recombinant erythropoietin on efficacy of preoperative chemoradiation therapy for squamous cell carcinoma of the oral cavity and oropharynx. Int. J. Radiat. Oncol. Biol. Phys. 50, 705-715 (2001).
10. Stasi, R., Abriani, L., Beccaglia, P., Terzoli, E. & Amadori, S. Cancer-related fatigue: evolving concepts in evaluation and treatment. Cancer 98, 1786-1801 (2003).
11. Cella, D., Kallich, J., McDermott, A. & Xu, X. The longitudinal relationship of hemoglobin, fatigue and quality of life in anemic cancer patients: results from five randomized clinical trials. Ann. Oncol. 15, 979-986 (2004).
12. Leyland-Jones, B. Breast cancer trial with erythropoietin terminated unexpectedty. Lancet Oncol. 4, 459-460 (2003). An unanticipated increase in early deaths led to termination of this trial, but analysis of causality was confounded by an imbalance in risk factors between the treatment arms as well with other protocol deficiencies.
13. Henke, M. et al. Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trial. Lancet 362, 1255-1260 (2003). Anaemia correction was achieved at the expense of inferior survival, but an imbalance in risk factors, poor overall survival and inappropriate starting and target haemoglobin levels prevent definitive conclusions.
14. Conrad, M. E. & Crosby. The natural history of iron deficiency induced by phlebotomy. Blood 20, 173-185 (1962).
15. Moliterno, A. R. & Spivak, J. L. in Scientific Basis of Transfusion Medicine, (eds Anderson, K. C. & Ness, P. M.) 1-12 (W. B. Saunders, Philadelphia, 2000).
16. Roberts, R. et al. Heparan sulphate bound growth factors: a mechanism for stromal cell mediated haemopoiesis. Nature 332, 376-378 (1988).
17. Reissmann, K. R. Studies on the mechanism of erythropoietic stimulation in parabiotic rats during hypoxia. Blood 5, 372-380 (1950).
18. Wang, G. L. & Semenza, G. L. Purification and characterization of hypoxia-inducible factor 1. J. Biol. Chem. 270, 1230-1237 (1995).
19. Harris, A. L. Hypoxia - a key regulatory factor in tumour growth. Nature Rev. Cancer 2, 38-47 (2002).
20. Semenza, G. L. Targeting HIF-1 for cancer therapy. Nature Rev. Cancer 3, 721-732 (2003).
21. Bondurant, M. C. & Koury, M. J. Anemia induces accumulation of erythropoietin mRNA in the kidney and liver. Mol. Cell. Biol. 6, 2731-2733 (1986).
22. Koury, S. T., Koury, M. J., Bondurant, M. C., Caro, J. & Graber, S. E. Quantitation of erythropoietin-producing cells in kidneys of mice by in situ hybridization: correlation with hematocrit, renal erythropoietin mRNA, and serum erythropoietin concentration. Blood 74, 645-651 (1989).
23. Koury, S. T., Bondurant, M. C., Koury, M. J. & Semenza, G. L. Localization of cells producing erythropoietin in murine liver by in situ hybridization. Blood 77, 2497-2503 (1991).
24. Tan, C. C., Eckardt, K. U., Firth, J. D. & Ratcliffe, P. J. Feedback modulation of renal and hepatic erythropoietin mRNA in response to graded anemia and hypoxia. Am J. Physiol. 263, F474-F481 (1992).
25. Jewell, U. R. et al. Induction of HIF-1α in response to hypoxia is instantaneous. FASEB J. 15, 1312-1314 (2001).
26. Spivak, J. L. The clinical physiology of erythropoietin. Semin. Hematol. 30, 2-11 (1993).
27. Sawyer, S. T., Krantz, S. B. & Goldwasser, E. Binding and receptor-mediated endocytosis of erythropoietin in Friend virus-infected erythroid cells. J. Biol. Chem. 262, 5554-5562 (1987).
28. Chapel, S. H., Veng-Pedersen, P., Schmidt, R. L. & Widness, J. A. Receptor-based model accounts for phlebotomy-induced changes in erythropoietin pharmacokinetics. Exp. Hematol. 29, 425-431 (2001).
29. Singh, A. et al. Increased plasma viscosity as a reason for inappropriate erythropoietin formation. J. Clin. Invest. 91, 251-256 (1993).
30. Spivak, J. L. The blood in systemic disorders. Lancet 355, 1707-1712 (2000).
31. Maccio, A. et al. Hemoglobin levels correlate with interleukin-6 levels in patients with advanced untreated epithelial ovarian cancer: role of inflammation in cancer-related anemia. Blood (in the press).
32. Means, R. T. Jr & Krantz, S. B. Progress in understanding the pathogenesis of the anemia of chronic disease. Blood 80, 1639-1647 (1992).
33. Faquin, W. C., Schneider, T. J. & Goldberg, M. A. Effect of inflammatory cytokines on hypoxia-induced erythropoietin production. Blood 79, 1987-1994 (1992).
34. Vannucchi, A. M. et al. Inhibition of erythropoietin production in vitro by human interferon γ. Br. J. Haematol. 87, 18-23 (1994).
35. Frede, S., Fandrey, J., Pagel, H., Hellwig, T. & Jelkmann, W. Erythropoietin gene expression is suppressed after lipopolysaccharide or interleukin-1β injections in rats. Am. J. Physiol. 273, R1067-R1071 (1997).
36. Hellwig-Burgel, T., Rutkowski, K., Metzen, E., Fandrey, J. & Jelkmann, W. Interleukin-1β and tumour necrosis factor-α stimulate DNA binding of hypoxia-inducible factor-1. Blood 94, 1561-1567 (1999).
37. La Ferla, K., Reimann, C., Jelkmann, W. & Hellwig-Burgel, T. Inhibition of erythropoietin gene expression signalling involves the transcription factors GATA-2 and NF-κB. FASEB J. 16, 1811-1813 (2002).
38. Pisa, P., Stenke, L., Bernell, P., Hansson, M. & Hast, R. Tumour necrosis factor-α and interferon-γ in serum of multiple myeloma patients. Anticancer Res. 10, 817-820 (1990).
39. Xia, Y., Feng, L., Yoshimura, T. & Wilson, C. B. LPS-induced MCP-1, IL-1β, and TNF-α mRNA expression in isolated erythrocyte-perfused rat kidney. Am. J. Physiol. 264, F774-F780 (1993).
40. Herrmann, F., Gebauer, G., Lindemann, A., Brach, M. & Mertelsmann, R. Interleukin-2 and interferon-γ recruit different subsets of human peripheral blood monocytes to secrete interleukin-1β and tumour necrosis factor-α. Clin. Exp. Immunol. 77, 97-100 (1989).
41. Means, R. T. Jr & Krantz, S. B. Inhibition of human erythroid colony-forming units by tumour necrosis factor requires β interferon. J. Clin. Invest. 91, 416-419 (1993).
42. Aulitzky, W. E. et al. Enhanced serum levels of β-2-microglobulin, neopterin, and interferon-γ in patients treated with recombinant tumour necrosis factor-α. J. Interferon Res. 8, 655-664 (1988).
43. Panzer, S., Madden, M. & Matsuki, K. Interaction of IL-1β, IL-6 and tumour necrosis factor-α (TNF-α) in human T cells activated by murine antigens. Clin. Exp. Immunol. 93, 471-478 (1993).
44. Furmanski, P. & Johnson, C. S. Macrophage control of normal and leukemic erythropoiesis: identification of the macrophage-derived erythroid suppressing activity as interleukin-1 and the mediator of its in vivo action as tumour necrosis factor. Blood 75, 2328-2334 (1990).
45. Johnson, C. S., Pourbohloul, S. C. & Furmanski, P. Negative regulators of in vivo erythropoiesis: interaction of IL-1α and TNF-α and the lack of a strict requirement for T or NK cells for their activity. Exp. Hematol. 19, 101-105 (1991).
46. Nicolas, G. et al. The gene encoding the iron regulatory peptide hepcidin is regulated by anemia, hypoxia, and inflammation. J. Clin. Invest. 110, 1037-1044 (2002). Anaemia and hypoxia downregulate hepcidin expression and increase iron availability, whereas inflammation upregulates hepcidin expression and reduces iron availability.
47. Kling, P. J. et al. Iron deprivation increases erythropoietin production in vitro, in normal subjects and patients with malignancy. Br. J. Haematol. 95, 241-248 (1996).
48. Miller, C. B., Jones, R. J., Piantadosi, S., Abeloff, M. D. & Spivak, J. L. Decreased erythropoietin response in patients with the anemia of cancer. N. Engl. J. Med. 322, 1689-1692 (1990). Cancer blunts the feedback relationship between tissue hypoxia and renal erythropoietin.
49. Rizzo, J. D. et al. Use of epoetin in patients with cancer: evidence-based clinical practice guidelines of the American Society of Clinical Oncology and the American Society of Hematology. Blood 100, 2303-2320 (2002). Meta-analysis of the clinical use of recombinant erythropoietin in the treatment of cancer-associated anaemia.
50. Quirt, I. et al. Epoetin alfa therapy increases hemoglobin levels and improves quality of life in patients with cancer-related anemia who are not receiving chemotherapy and patients with anemia who are receiving chemotherapy. J. Clin. Oncol. 19, 4126-4134 (2001).
51. Dainiak, N. et al. Mechanisms of abnormal erythropoiesis in malignancy. Cancer 51, 1101-1106 (1983).
52. Bazan, J. F. Structural design and molecular evolution of a cytokine receptor superfamily. Proc. Natl. Acad. Sci. USA 87, 6934-6938 (1990).
53. Remy, I., Wilson, I. A. & Michnick, S. W. Erythropoietin receptor activation by a ligand-induced conformation change. Science 283, 990-993 (1999).
54. Koury, M. J. & Bondurant, M. C. Erythropoietin retards DNA breakdown and prevents programmed death in erythroid progenitor cells. Science 248, 378-381 (1990). Erythropoietin is a survival factor for late erythroid progenitor cells.
55. Ullrich, A. & Schlessinger, J. Signal transduction by receptors with tyrosine kinase activity. Cell 61, 203-212 (1990).
56. Smith, M. A., Court E. L. & Smith, J. G. Stem cell factor: laboratory and clinical aspects. Blood Rev. 15, 191-197 (2001).
57. Dal, C. H., Price, J. O., Brunner, T. & Krantz, S. B. Fas ligand is present in human erythroid colony-forming cells and interacts with Fas induced by interferon γ to produce erythroid cell apoptosis. Blood 91, 1235-1242 (1998).
58. Choi, I. et al. Interferon γ delays apoptosis of mature erythroid progenitor cells in the absence of erythropoietin. Blood 95, 3742-3749 (2000).
59. Dai, C. & Krantz, S. B. Interferon gamma induces upregulation and activation of caspases 1, 3, and 8 to produce apoptosis in human erythroid progenitor cells. Blood 93, 3309-3316 (1999).
60. Zamai, L. et al. TNF-related apoptosis-inducing ligand (TRAIL) as a negative regulator of normal human erythropoiesis. Blood 95, 3716-3724 (2000).
61. Secchiero, P. et al. TRAIL regulates normal erythroid maturation through an ERK-dependent pathway. Blood 103, 517-522 (2004).
62. Schmidt, U. et al. Btk Is Required for an efficient response to erythropoietin and for SCF-controlled protection against TRAIL in erythroid progenitors. J. Exp. Med. 199, 785-795 (2004).
63. Blick, M., Sherwin, S. A., Rosenblum, M. & Gutterman, J. Phase I study of recombinant tumour necrosis factor in cancer patients. Cancer Res. 47, 2986-2989 (1987).
64. Rusten, L. S. & Jacobsen, S. E. Tumour necrosis factor (TNF)-α directly inhibits human erythropoiesis in vitro: role of p55 and p75 TNF receptors. Blood 85, 989-996 (1995).
65. Moldawer, L. L. et al. Cachectin/tumour necrosis factor-α alters red blood cell kinetics and induces anemia in vivo. FASEB J. 3, 1637-1643 (1989).
66. Uddin, S., Ah-Kang, J., Ulaszek, J., Mahmud, D. & Wickrema, A. Differentiation stage-specific activation of p38 mitogen-activated protein kinase isoforms in primary human erythroid cells. Proc. Natl Acad. Sci. USA 101, 147-152 (2004).
67. Zermati, Y. et al. Caspase activation is required for terminal erythroid differentiation. J. Exp. Med. 193, 247-254 (2001). Controlled activation of a death effector protease is essential for completion of erythroid differentiation.
68. Gupta, S. Molecular signalling in death receptor and mitochondrial pathways of apoptosis (review). Int. J. Oncol. 22, 15-20 (2003).
69. Kapur, R. & Zhang, L. A novel mechanism of cooperation between c-Kit and erythropoietin receptor. Stem cell factor induces the expression of Stat5 and erythropoietin receptor, resulting in efficient proliferation and survival by erythropoietin. J. Biol. Chem. 276, 1099-1106 (2001). Synergistic interaction of two growth factor receptors essential for erythropoiesis.
70. Budd, R. C. Death receptors couple to both cell proliferation and apoptosis. J. Clin. Invest 109, 437-441 (2002).
71. Koury, M. J. & Bondurant, M. C. The molecular mechanism of erythropoietin action. Eur. J. Biochem. 210, 649-663 (1992).
72. De Maria, R. et al. Apoptotic role of Fas/Fas ligand system in the regulation of erythropoiesis. Blood 93, 796-803 (1999). Differential regulation of FAS and its ligand during erythroid differentiation.
73. Crosby, W. H. & Akeroyd, J. H. The limit of hemoglobin synthesis in hereditary hemolytic anemia; its relation to the excretion of bile pigment. Am. J. Med. 13, 273-283 (1952).
74. Hyman, G. A. Anemia in malignant neoplastic disease. J. Chronic. Dis. 16, 645-666 (1963).
75. Moliterno, A. R. & Spivak, J. L. Anemia of cancer. Hematol. Oncol. Clin. North Am. 10, 345-363 (1996).
76. Reiner, A. P. & Spivak, J. L. Hematophagic histiocytosis. A report of 23 new patients and a review of the literature. Medicine (Baltimore) 67, 369-388 (1988).
77. Cartwright, G. E. The anemia of chronic disorders. Semin. Hematol. 3, 351-375 (1966).
78. Cash, J. M. & Sears, D. A. The anemia of chronic disease: spectrum of associated diseases in a series of unselected hospitalized patients. Am. J. Med. 87, 638-644 (1989). The anaemia of chronic disease encompasses a wider range of disorders than initially recognized.
79. Denz, H. et al. Correlation between neopterin, interferon-γ and haemoglobin in patients with haematological disorders. Eur. J. Haematol. 44, 186-189 (1990).
80. Balkwill, F. et al. Evidence for tumour necrosis factor/ cachectin production in cancer. Lancet 2, 1229-1232 (1987).
81. Jason, J. et al. Comparison of serum and cell-specific cytokines in humans. Clin. Diagn. Lab. Immunol. 8, 1097-1103 (2001).
82. Roodman, G. D., Horadam, V. W. & Wright, T. L. Inhibition of erythroid colony formation by autologous bone marrow adherent cells from patients with the anemia of chronic disease. Blood 62, 406-412 (1983).
83. Claessens, Y. E. et al. In vitro proliferation and differentiation of erythroid progenitors from patients with myelodysplastic syndromes: evidence for Fas-dependent apoptosis. Blood 99, 1594-1601 (2002).
84. Kitagawa, M. et al. Localization of Fas and Fas ligand in bone marrow cells demonstrating myelodysplasia. Leukemia 12, 486-492 (1998).
85. Campioni, D. et al. Evidence for a role of TNF-related apoptosis-inducing ligand (TRAIL) in the anemia of myelodysplastic syndromes. Am. J. Pathol. 166, 557-563 (2005).
86. Johnson, R. A., Waddelow, T. A., Caro, J., Oliff, A. & Roodman, G. D. Chronic exposure to tumour necrosis factor in vivo preferentially inhibits erythropoiesis in nude mice. Blood 74, 130-138 (1989).
87. + cells. Exp. Hematol. 30, 1238-1247 (2002).
88. Means, R. T. Jr, Dessypris, E. N. & Krantz, S. B. Inhibition of human erythroid colony-forming units by interleukin-1 is mediated by γ interferon. J. Cell Physiol. 150, 59-64 (1992).
89. + hematopoietic cells and their modulation by tumour necrosis factor-α and interferon-γ. Blood 92, 3073-3081 (1998).
90. Gibellini, D. et al. Stroma-derived factor 1α induces a selective inhibition of human erythroid development via the functional upregulation of Fas/CD95 ligand. Br. J. Haematol. 111, 432-440 (2000).
91. Herbeuval, J. P. et al. Macrophages from cancer patients: analysis of TRAIL, TRAIL receptors, and colon tumour cell apoptosis. J. Natl. Cancer Inst. 95, 611-621 (2003).
92. - highly malignant plasma cells: a major pathogenetic mechanism of anemia in multiple myeloma. Blood 99, 1305-1313 (2002).
93. Silvestris, F., Tucci, M., Cafforio, P. & Dammacco, F. Fas-L upregulation by highly malignant myeloma plasma cells: role in the pathogenesis of anemia and disease progression. Blood 97, 1155-1164 (2001).
94. Busch, M. P., Kleinman, S. H. & Nemo, G. J. Current and emerging infectious risks of blood transfusions. JAMA 289, 959-962 (2003).
95. Pealer, L. N. et al. Transmission of West Nile virus through blood transfusion in the United States in 2002. N. Engl. J. Med. 349, 1236-1245 (2003).
96. Barlett, D. L. & Steele, J. B. Why we pay so much for drugs. Time 163, 45-52 (2004).
97. Eschbach, J. W. et al. Recombinant human erythropoietin in anemic patients with end-stage renal disease. Results of a phase III multicenter clinical trial. Ann. Intern. Med. 111, 992-1000 (1989).
98. Vaziri, N. D. Cardiovascular effects of erythropoietin and anemia correction. Curr. Opin. Nephrol. Hypertens. 10, 633-637 (2001).
99. Rossert, J., Casadevall, N. & Eckardt, K. U. Anti-erythropoietin antibodies and pure red cell aplasia. J. Am. Soc. Nephrol. 15, 398-406 (2004).
100. Chikuma, M., Masuda, S., Kobayashi, T., Nagao, M. & Sasaki, R. Tissue-specific regulation of erythropoietin production in the murine kidney, brain, and uterus. Am. J. Physiol. Endocrinol. Metab. 279, E1242-E1248 (2000).
101. Graeber, T. G. et al. Hypoxia induces accumulation of p53 protein, but activation of a G1-phase checkpoint by low-oxygen conditions is independent of p53 status. Mol. Cell. Biol. 14, 6264-6277 (1994).
102. Ravi, R. et al. Regulation of tumour angiogenesis by p53-induced degradation of hypoxia-inducible factor 1α. Genes Dev. 14, 34-44 (2000). Loss of p53 function enhances HIF1α expression and activity.
103. Erbayraktar, S., Yilmaz, O., Gokmen, N. & Brines, M. Erythropoietin is a multifunctional tissue-protective cytokine. Curr. Hematol. Rep. 2, 465-470 (2003).
104. Ehrenreich, H. et al. Erythropoietin therapy for acute stroke is both safe and beneficial. Mol. Med. 8, 495-505 (2002).
105. Vaupel, P., Kelleher, D. K. & Hockel, M. Oxygen status of malignant tumours: pathogenesis of hypoxia and significance for tumour therapy. Semin. Oncol. 28, 29-35 (2001).
106. 2 gradients in solid tumours in vivo: high-resolution measurements reveal a lack of correlation. Nature Med. 3, 177-182 (1997). Hypoxia can be present in well-perfused tumours.
107. Mizukami, Y. et al. Hypoxia-inducible factor-1-independent regulation of vascular endothelial growth factor by hypoxia in colon cancer. Cancer Res. 64, 1765-1772 (2004).
108. Hopfl, G. et al. Rescue of hypoxia-inducible factor-1α-deficient tumour growth by wild-type cells is independent of vascular endothelial growth factor. Cancer Res. 62, 2962-2970 (2002).
109. Zhong, H. et al. Overexpression of hypoxia-inducible factor 1α in common human cancers and their metastases. Cancer Res. 59, 5830-5835 (1999).
110. Birner, P. et al. Overexpression of hypoxia-inducible factor 1α is a marker for an unfavourable prognosis in early-stage invasive cervical cancer. Cancer Res. 60, 4693-4696 (2000).
111. Ryan, H. E. et al. Hypoxia-inducible factor-1α is a positive factor in solid tumour growth. Cancer Res. 60, 4010-4015 (2000).
112. Koukourakis, M. I. et al. Hypoxia-inducible factor (HIF1A and HIF2A), angiogenesis, and chemoradiotherapy outcome of squamous cell head-and-neck cancer. Int. J. Radiat. Oncol. Biol. Phys. 53, 1192-1202 (2002).
113. Aebersold, D. M. et al. Expression of hypoxia-inducible factor-1α: a novel predictive and prognostic parameter in the radiotherapy of oropharyngeal cancer. Cancer Res. 61, 2911-2916 (2001). Overexpression of HIF1α is an adverse prognostic marker in certain tumour types.
114. Giatromanolaki, A. et al. Relation of hypoxia inducible factor 1α and 2α in operable non-small cell lung cancer to angiogenic/molecular profile of tumours and survival. Br. J. Cancer 85, 881-890 (2001).
115. Acs, G. et al. Hypoxia-inducible erythropoietin signalling in squamous dysplasia and squamous cell carcinoma of the uterine cervix and its potential role in cervical carcinogenesis and tumour progression. Am. J. Pathol. 162, 1789-1806 (2003).
116. Acs, G., Zhang, P. J., Rebbeck, T. R., Acs, P. & Verma, A. Immunohistochemical expression of erythropoietin and erythropoietin receptor in breast carcinoma. Cancer 95, 969-981 (2002).
117. Westenfelder, C. & Baranowski, R. L. Erythropoietin stimulates proliferation of human renal carcinoma cells. Kidney Int. 58, 647-657 (2000).
118. Yasuda, Y. et al. Erythropoietin is involved in growth and angiogenesis in malignant tumours of female reproductive organs. Carcinogenesis 23, 1797-1805 (2002).
119. Yasuda, Y. et al. Inhibition of erythropoietin signalling destroys xenografts of ovarian and uterine cancers in nude mice. Br. J. Cancer 84, 836-843 (2001).
120. Hockel, M. et al. Association between tumour hypoxia and malignant progression in advanced cancer of the uterine cervix. Cancer Res. 56, 4509-4515 (1996).
121. Graeber, T. G. et al. Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours. Nature 379, 88-91 (1996). Hypoxia selects for p53-deficient tumour cells.
122. Becker, A. et al. Severe anemia is associated with poor tumour oxygenation in head and neck squamous cell carcinomas. Int. J. Radiat. Oncol. Biol. Phys. 46, 459-466 (2000).
123. Obermair, A. et al. Impact of hemoglobin levels before and during concurrent chemoradiotherapy on the response of treatment in patients with cervical carcinoma: preliminary results. Cancer 92, 903-908 (2001).
124. Lutterbach, J. & Guttenberger, R. Anemia is associated with decreased local control of surgically treated squamous cell carcinomas of the glottic larynx. Int. J. Radiat. Oncol. Biol. Phys. 48, 1345-1350 (2000).
125. Henke, M., Sindlinger, F., Ikenberg, H., Gerds, T. & Schumacher, M. Blood hemoglobin level and treatment outcome of early breast cancer. Strahlenther. Onkol. 180, 45-51 (2004).
126. Altun, M. et al. Prognostic significance of hemoglobin concentration in nasopharyngeal carcinoma: does treatment-induced anemia have negative effect? In Vivo 17, 483-487 (2003).
127. Schafer, U., Micke, O., Muller, S. B., Schuller, P. & Willich, N. Hemoglobin as an independent prognostic factor in the radiotherapy of head and neck tumours. Strahlenther. Onkol. 179, 527-534 (2003).
128. Obermair, A. et al. Anemia before and during concurrent chemoradiotherapy in patients with cervical carcinoma: effect on progression-free survival. Int. J. Gynecol. Cancer 13, 633-639 (2003).
129. Grogan, M. et al. The importance of hemoglobin levels during radiotherapy for carcinoma of the cervix. Cancer 86, 1528-1536 (1999).
130. Chua, D. T., Sham, J. S. & Choy, D. T. Prognostic impact of hemoglobin levels on treatment outcome in patients with nasopharyngeal carcinoma treated with sequential chemoradiotherapy or radiotherapy alone. Cancer 101, 307-316 (2004).
131. Wagner, W. et al. Prognostic value of hemoglobin concentrations in patients with advanced head and neck cancer treated with combined radio-chemotherapy and surgery. Strahlenther. Onkol. 176, 73-80 (2000).
132. Kelleher, D. K., Mattheinsen, U., Thews, O. & Vaupel, P. Blood flow, oxygenation, and bioenergetic status of tumours after erythropoietin treatment in normal and anemic rats. Cancer Res. 56, 4728-4734 (1996).
133. Blackwell, K. L. et al. Human recombinant erythropoietin significantly improves tumour oxygenation independent of its effects on hemoglobin. Cancer Res. 63, 6162-6165 (2003).
134. Thews, O., Kelleher, D. K. & Vaupel, P. Erythropoietin restores the anemia-induced reduction in cyclophosphamide cytotoxicity in rat tumours. Cancer Res. 61, 1358-1361 (2001).
135. Silver, D. F. & Piver, M. S. Effects of recombinant human erythropoietin on the antitumour effect of cisplatin in SCID mice bearing human ovarian cancer: a possible oxygen effect. Gynecol. Oncol. 73, 280-284 (1999).
136. Stuben, G. et al. Recombinant human erythropoietin increases the radiosensitivity of xenografted human tumours in anaemic nude mice. J. Cancer Res. Clin. Oncol. 127, 346-350 (2001).
137. Van Halteren, H. K. et al. Recombinant human erythropoietin attenuates weight loss in a murine cancer cachexia model. J. Cancer Res. Clin. Oncol. 130, 211-216 (2004).
138. Mittelman, M., Neumann, D., Peled, A., Kanter, P. & Haran-Ghera, N. Erythropoietin induces tumour regression and antitumour immune responses in murine myeloma models. Proc. Natl Acad. Sci. USA 98, 5181-5186 (2001).
139. Littlewood, T. J., Bajetta, E., Nortier, J. W., Vercammen, E. & Rapoport, B. Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: results of a randomized, double-blind, placebo-controlled trial. J. Clin. Oncol. 19, 2865-2874 (2001). Influential controlled clinical trial of recombinant erythropoietin in anaemic cancer patients.
140. Kaanders, J. H. & van der Kogel, A. J. Erythropoietin to treat anaemia in patients with head and neck cancer. Lancet 363, 78-79 (2004).
141. Haddad, R. & Posner, M. Erythropoietin to treat anaemia in patients with head and neck cancer. Lancet 363, 79-80 (2004).
142. Leyland-Jones, B. & Mahmud, S. Erythropoietin to treat anaemia in patients with head and neck cancer. Lancet 363, 80-82 (2004).
143. Vaupel, P. & Mayer, A. Erythropoietin to treat anaemia in patients with head and neck cancer. Lancet 363, 992 (2004).
144. Liu, W. M. et al. Effect of haemopoietic growth factors on cancer cell lines and their role in chemosensitivity. Oncogene 23, 981-990 (2004).
145. Asano, Y., Okamura, S., Shibuya, T., Harada, M. & Niho, Y. Growth of clonogenic myeloblastic leukemic cells in the presence of human recombinant erythropoietin in addition to various human recombinant hematopoietic growth factors. Blood 72, 1682-1686 (1988).
146. Ribatti, D. et al. Human erythropoietin induces a proangiogenic phenotype in cultured endothelial cells and stimulates neovascularization in vivo. Blood 93, 2627-2636 (1999).
147. Gordeuk, V. R. et al. Congenital disorder of oxygen sensing: association of the homozygous Chuvash polycythemia VHL mutation with thrombosis and vascular abnormalities but not tumours. Blood 103, 3924-3932 (2004).
148. Ludwig, H. et al. Erythropoietin treatment of anemia associated with multiple myeloma. N. Engl. J. Med. 322, 1693-1699 (1990).
149. Seidenfeld, J. et al. Epoetin treatment of anemia associated with cancer therapy: a systematic review and meta-analysis of controlled clinical trials. J. Natl Cancer Inst. 93, 1204-1214 (2001).
150. Hampton, G. M. & Frierson, H. F. Classifying human cancer by analysis of gene expression. Trends Mol. Med. 9, 5-10 (2003).
151. Mocellin, S., Rossi, C. R., Pilati, P. & Nitti, D. Tumour necrosis factor, cancer and anticancer therapy. Cytokine Growth Factor Rev. 16, 35-53 (2005).
152. Wajant, H., Pfizenmaier, K. & Scheurich, P. TNF-related apoptosis inducing ligand (TRAIL) and its receptors in tumour surveillance and cancer therapy. Apoptosis. 7, 449-459 (2002).
153. Miyazawa, K. et al. Membrane-bound Steel factor induces more persistent tyrosine kinase activation and longer life span of c-kit gene-encoded protein than its soluble form. Blood 85, 641-649 (1995).
154. Jacobs-Helber, S. M., Penta, K., Sun, Z., Lawson, A. & Sawyer, S. T. Distinct signalling from stem cell factor and erythropoietin in HCD57 cells. J. Biol. Chem. 272, 6850-6853 (1997).
155. Pircher, T. J. et al. Integrative signalling by minimal erythropoietin receptor forms and c-Kit. J. Biol. Chem. 276, 8995-9002 (2001).
156. Boer, A. K., Drayer, A. L. & Vellenga, E. Stem cell factor enhances erythropoietin-mediated transactivation of signal transducer and activator of transcription 5 (STAT5) via the PKA/CREB pathway. Exp. Hematol. 31, 512-520 (2003).
157. Sui, X., Krantz, S. B., You, M. & Zhao, Z. Synergistic activation of MAP kinase (ERK1/2) by erythropoietin and stem cell factor is essential for expanded erythropoiesis. Blood 92, 1142-1149 (1998).
158. + human primary erythroid cells from apoptosis. Exp. Hematol. 29, 833-841 (2001).
159. Tan, B. L., Hong, L., Munugalavadla, V. & Kapur, R. Functional and biochemical consequences of abrogating the activation of multiple diverse early signalling pathways in Kit. Role for Src kinase pathway in Kit-induced cooperation with erythropoietin receptor. J. Biol. Chem. 278, 11686-11695 (2003).
160. + bone marrow cells in the absence of detectable cell differentiation. Stem Cells 19, 59-70 (2001).
161. Tang, T., Prasad, K. S., Koury, M. J. & Brandt, S. J. Mitogen-activated protein kinase mediates erythropoietin-induced phosphorylation of the TAL1/SCL transcription factor in murine proerythroblasts. Biochem. J. 343, 615-620 (1999).
162. Lacronique, V. et al. Bcl-2 targeted overexpression into the erythroid lineage of transgenic mice delays but does not prevent the apoptosis of erythropoietin-deprived erythroid progenitors. Blood 90, 3050-3056 (1997).
163. Sui, X., Krantz, S. B. & Zhao, Z. J. Stem cell factor and erythropoietin inhibit apoptosis of human erythroid progenitor cells through different signalling pathways. Br. J. Haematol. 110, 63-70 (2000).
164. Chung, I. J., Dai, C. & Krantz, S. B. Stem cell factor increases the expression of FLIP that inhibits IFNγ-induced apoptosis in human erythroid progenitor cells. Blood 101, 1324-1328 (2003).
165. Somervaille, T. C., Linch, D. C. & Khwaja, A. Growth factor withdrawal from primary human erythroid progenitors induces apoptosis through a pathway involving glycogen synthase kinase-3 and Bax. Blood 98, 1374-1381 (2001).
166. Paulson, R. F., Vesely, S., Siminovitch, K. A. & Bernstein, A. Signalling by the W/Kit receptor tyrosine kinase is negatively regulated in vivo by the protein tyrosine phosphatase Shp1. Nature Genet. 13, 309-315 (1996).
167. Nicolas, G. et al. Severe iron deficiency anemia in transgenic mice expressing liver hepcidin. Proc. Natl Acad. Sci. USA 99, 4596-4601 (2002).
168. Nemeth, E. et al. IL-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin. J. Clin. Invest 113, 1271-1276 (2004).
169. Freireich, E. J., Miller, A., Emerson, C. P. & Ross, J. F. The effect of inflammation or the utilization of erythrocyte and transferrin bound radioiron for red cell production. Blood 12, 972-983 (1957).
170. Weinstein, D. A. et al. Inappropriate expression of hepcidin is associated with iron refractory anemia: implications for the anemia of chronic disease. Blood 100, 3776-3781 (2002).
171. Andrews, N. C. Anemia of inflammation: the cytokine-hepcidin link. J. Clin. Invest. 113, 1251-1253 (2004).
172. Cazzola, M. et al. Defective iron supply for erythropoiesis and adequate endogenous erythropoietin production in the anemia associated with systemic-onset juvenile chronic arthritis. Blood 87, 4824-4830 (1996).
173. Nieken, J. et al. Recombinant human interleukin-6 induces a rapid and reversible anemia in cancer patients. Blood 86, 900-905 (1995).
174. Atkins, M. B., Kappler, K., Mier, J. W., Isaacs, R. E. & Berkman, E. M. Interleukin-6-associated anemia: determination of the underlying mechanism. Blood 86, 1288-1291 (1995).
175. Wang, G. L. & Semenza, G. L. Desferrioxamine induces erythropoietin gene expression and hypoxia-inducible factor 1 DNA-binding activity: implications for models of hypoxia signal transduction. Blood 82, 3610-3615 (1993). Iron is an essential regulatory factor for HIF1α degradation.
176. Salvarani, C. et al. Effects of desferrioxamine therapy on chronic disease anemia associated with rheumatoid arthritis. Rheumatol. Int. 16, 45-48 (1996).
177. Pincus, T. et al. Multicenter study of recombinant human erythropoietin in correction of anemia in rheumatoid arthritis. Am. J. Med. 89, 161-168 (1990).
178. + hematopoietic progenitor cells. Exp. Hematol. 30, 990-1000 (2002).
179. Bouscary, D. et al. Critical role for PI 3-kinase in the control of erythropoietin-induced erythroid progenitor proliferation. Blood 101, 3436-3443 (2003).
180. Carroll, M. P. et al. Erythropoietin induces Raf-1 activation and Raf-1 is required for erythropoietin-mediated proliferation. J. Biol. Chem. 266, 14964-14969 (1991).
181. Van Den, A. E. et al. Tyrosine kinase receptor RON functions downstream of the erythropoietin receptor to induce expansion of erythroid progenitors. Blood 103, 4457-4465 (2004).
182. Von Lindern, M. et al. Protein kinase Cα controls erythropoietin receptor signalling. J. Biol. Chem. 275, 34719-34727 (2000).
183. + progenitor cells from human bone marrow. Blood 95, 510-518 (2000).
184. -/- mice due to decreased survival of early erythroblasts. Blood 98, 3261-3273 (2001). BCL-XL is an essential factor for erythroid-cell differentiatiation.
185. Nagata, Y., Takahashi, N., Davis, R. J. & Todokoro, K. Activation of p38 MAP kinase and JNK but not ERK is required for erythropoietin-induced erythroid differentiation. Blood 92, 1859-1869 (1998).
186. Kolbus, A. et al. Raf-1 antagonizes erythroid differentiation by restraining caspase activation. J. Exp. Med. 196, 1347-1353 (2002).
187. Uddin, S., Kottegoda, S., Stigger, D., Platanias, L. C. & Wickrema, A. Activation of the Akt/FKHRL1 pathway mediates the antiapoptotic effects of erythropoietin in primary human erythroid progenitors. Biochem. Biophys. Res. Commun. 275, 16-19 (2000).
188. Kashii, Y. et al. A member of Forkhead family transcription factor, FKHRL1, is one of the downstream molecules of phosphatidylinositol 3-kinase-Akt activation pathway in erythropoietin signal transduction. Blood 96, 941-949 (2000).
189. Dijkers, P. F. et al. FKHR-L1 can act as a critical effector of cell death induced by cytokine withdrawal: protein kinase B-enhanced cell survival through maintenance of mitochondrial integrity. J. Cell Biol. 156, 531-542 (2002).
190. Zeuner, A. et al. Control of erythroid cell production via caspase-mediated cleavage of transcription factor SCL/Tal-1. Cell Death. Differ. 10, 905-913 (2003). SCL/TAL-1 is an essential anti-apoptotic factor in erythroid progenitor cells.
191. l and apopain in the control of erythropoiesis by erythropoietin. Blood 90, 630-640 (1997).